India and Brazil exchanged a Memorandum of Understanding to strengthen bilateral cooperation in the regulation of pharmaceutical and medical products, marking a significant step in expanding regulatory collaboration between the two countries.
The MoU was exchanged between the Central Drugs Standard Control Organisation and the Brazilian Health Regulatory Agency ANVISA at Hyderabad House. The exchange took place between Leandro Safatle, Director President of ANVISA, and Dinesh Bhatia, Indian Ambassador to Brazil, in the presence of Prime Minister Narendra Modi and President Luiz Inácio Lula da Silva.
The agreement establishes a structured framework for cooperation and information exchange in the regulation of medical products, including pharmaceutical ingredients, drugs, biological products and medical devices. It seeks to promote greater convergence in regulatory practices, enhance mutual understanding of regulatory systems and facilitate coordinated oversight of medical products in both countries.
Officials indicated that the MoU reflects the shared commitment of India and Brazil to ensuring the availability of safe, effective and quality assured medicines and medical products for their populations. The agreement is expected to strengthen supply chains, encourage adoption of regulatory best practices and support wider access to affordable healthcare solutions.
The framework also provides for cooperation in areas such as information sharing, regulatory capacity building and collaboration on matters related to pharmaceutical and medical product regulation, in accordance with the respective national laws and regulations of both countries.
The MoU builds on the broader India–Brazil cooperation in the health sector and complements existing institutional mechanisms for bilateral engagement. It underscores the growing collaboration between the two nations in health, pharmaceuticals and medical technologies, aligned with their shared priorities as leading partners in the Global South.
The exchange of the agreement is expected to further consolidate India–Brazil relations, open new avenues for collaboration in the health and pharmaceutical sectors and contribute to improved public health outcomes in both countries.
